Lineage Cell Therapeutics, Inc.
LCTXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 14, 2026 |
| D. Boral Capital | maintain | Buy | May 4, 2026 |
| B. Riley Securities | maintain | Buy | Mar 25, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2026 |
| D. Boral Capital | maintain | Buy | Mar 6, 2026 |
| D. Boral Capital | maintain | Buy | Feb 9, 2026 |
| D. Boral Capital | maintain | Buy | Nov 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 24, 2025 |
| D. Boral Capital | maintain | Buy | Aug 27, 2025 |
| D. Boral Capital | maintain | Buy | Aug 14, 2025 |
| D. Boral Capital | maintain | Buy | Aug 5, 2025 |
| D. Boral Capital | maintain | Buy | Jun 23, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 23, 2025 |
| B. Riley Securities | maintain | Buy | Mar 14, 2025 |
| D. Boral Capital | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 11, 2025 |
| D. Boral Capital | maintain | Buy | Feb 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 31, 2025 |
| Maxim Group | maintain | Buy | Jan 10, 2025 |
| D. Boral Capital | maintain | Buy | Jan 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 4, 2024 |
| D. Boral Capital | maintain | Buy | Nov 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 8, 2024 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.03| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.03 | $-0.03 | $1.1M | $1.8M |
| May 12, 2026 | $-0.03 | $-0.02 | $1.7M | $3.6M |
| Mar 5, 2026 | $0.00 | $-0.04 | $6.6M | $2.0M |
| Nov 6, 2025 | $-0.13 | $-0.02 | $3.7M | $2.0M |
| Aug 12, 2025 | $-0.01 | $-0.02 | $2.8M | $1.5M |
| May 13, 2025 | $-0.02 | $-0.02 | $1.5M | $1.7M |
| Mar 10, 2025 | $-0.01 | $-0.04 | $2.9M | $1.6M |
| Nov 14, 2024 | $-0.02 | $-0.01 | $3.8M | $1.6M |
News
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on ReSonance (ANP1), the Company's first internally-developed cell transplant program, for the treatment of hearing loss built on its patented and proprietary AlloSCOPE™ manufacturing platform, currently bein…
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) shares were up 8.7% during trading on Friday. The company traded as high as $1.04 and last traded at $1.03. Approximately 2,480,587 shares traded hands during trading, an increase of 101% from the average daily volume of 1,231,612 shares. The stock had previously closed at $0.9478.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.